Breast Cancer

BRCA1/2 Status in Response to Therapy in Triple-Negative Breast Cancer

An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy...

Breast Cancer

5-Year Outcomes With Extended Adjuvant Therapy in HER2-Positive Breast Cancer

The 5-year analysis of the phase III ExteNET trial has shown that 1 year of neratinib  after trastuzumab-based adjuvant...

Lung Cancer

ESMO Asia 2017: Alectinib More Effective Than Crizotinib in Asian Patients With ALK-Positive NSCLC

A subanalysis of the phase III ALEX study has shown that alectinib is more effective than the standard of care, crizotinib...


Advertisement

More Top Stories

Palliative Care

Michael Hoerger, PhD, on Early Palliative Care: Study Results

Solid Tumors
Breast Cancer

Where Are We Now in Triple-Negative Breast Cancer?

The treatment of triple-negative breast cancer is rapidly evolving, as clinical trials continue to test chemotherapy agents and combinations and immunotherapy studies promise potentially “game-changing” interventions early in the course of disease, Joyce O’Shaughnessy, MD, reported at the 19th...

Advertisement

ESMO Asia 2017: FLAURA Trial: Osimertinib Improves Progression-Free Survival in Asian Patients With EGFR-Mutated NSCLC

Osimertinib (Tagrisso) improves progression-free survival compared to standard first-line therapy in Asian patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the European Society for Medical Oncology (ESMO)...

Prostate Cancer

Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

Genomics/Genetics
Solid Tumors
Lymphoma
Multiple Myeloma

Update on NCI-MATCH Precision Medicine Trial

THE NATIONAL CANCER INSTITUTE (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented at the 2017 American Association for Cancer Research–NCI–European Organisation for Research...

Restorative Effects of Painting Offset the Demands of Oncology

Oncologists are apt to give patients the worst news of their lives: You have cancer. Yet studies show that, by and large, despite the stressful aspects of treating people with a life-threatening disease, oncologists report one of the highest percentages of professional satisfaction among medical...

ESMO Asia 2017: AXEPT Trial: New Second-Line Therapy for Metastatic Colorectal Cancer Is Effective and Safe

A randomized trial in 650 patients has confirmed the safety and efficacy of a new second-line treatment for metastatic colorectal cancer, researchers reported at the European Society for Medical Oncology (ESMO) Asia 2017 Congress (Abstract LBA3_PR). Oral fluorinated pyrimidines have been...

Skin Cancer

Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial

The Man in the Vest

It had been an uneventful Sunday morning, and I was writing my final note for the day, hopeful to make a stealth exit and perhaps join my family at church. But as I closed the chart and looked up, I saw Ruthie, my oncology fellow, approaching with a grim expression. “I just left the room of a...

Advertisement

Patient-Reported Outcomes With Immunotherapy vs Chemotherapy in Advanced NSCLC

Pembrolizumab (Keytruda) treatment was associated with improved or maintained health-related quality of life vs platinum-based chemotherapy in the phase III KEYNOTE-024 trial in advanced programmed cell death ligand 1 (PD-L1)–positive non–small cell lung cancer (NSCLC). These findings...